Overview

A Study of Two Different Formulations of LY3209590 in Healthy Participants

Status:
Completed
Trial end date:
2021-09-03
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to look at the amount of the study drug, LY3209590, that gets into the blood stream and how long it takes the body to get rid of LY3209590 when given as different formulations. The tolerability of LY3209590 will also be evaluated and information about any side effects experienced will be collected. The study will last up to 142 days.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company